Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 study of Lacutamab in CTCL

Next Previous
Trial Profile

A Phase 3 study of Lacutamab in CTCL

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lacutamab (Primary)
  • Indications T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms TELLOMAK 3

Most Recent Events

  • 16 Sep 2026 According to the Innate Pharma media release, Innate Pharma entered a strategic partnership with Sobi to license lacutamab in T-cell lymphoma. Transaction closing triggers the USD 75 million upfront payment and marks the initiation of the study.
  • 16 Sep 2026 According to the Innate Pharma media release, first patient expected to enroll in Q1 2027.
  • 10 Aug 2026 According to Swedish Orphan Biovitrum media release, , AaTELLOMAK-3 study will subsequently support applications for full approvals in key jurisdictions in Sezary syndrome and mycosis fungoides

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top